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We performed a prospective study of all inpatient and
outpatient methicillin-resistant Staphylococcus aureus
(MRSA) isolates identified at the University of Chicago
Hospitals from November 2003 through November 2004.
Differences in resistance to non–β-lactam antimicrobial
drugs were determined after stratification of the 578 MRSA
isolates into 4 groups by patient age (pediatric vs. adult)
and onset location (community vs. hospital). Non–β-lactam
resistance was significantly greater among the 288 adult
than the 177 pediatric community-associated isolates for
erythromycin (93.2 vs. 87.0%, p = 0.03), clindamycin (51.8
vs. 7.3%, p<0.001), ciprofloxacin (62.1 vs. 10.7%,
p<0.001), gentamicin (11.1 vs. 1.1%, p<0.001), and tetra-
cycline (19.9 vs. 6.4%, p<0.001). In contrast, hospital-asso-
ciated MRSA isolates from children and adults had similar
rates of non–β-lactam antimicrobial drug resistance. In our
region, clindamycin is an appropriate empiric therapy of
community-associated MRSA infection in children but
should be used with caution in adults. 
C
olonization by and infection with methicillin-resistant
Staphylococcus aureus (MRSA) in children and adults
who have little or no contact with the healthcare system,
phenomena almost unknown before the mid-1990s, have
been reported with increasing frequency (1–34). In some
cities and rural areas, rates of these community-associated
MRSA (CA-MRSA) infections, particularly in skin and
soft tissue, are increasing rapidly (1–4). Many CA-MRSA
infections have been attributed to isolates that are distinct
from hospital-associated MRSA (HA-MRSA) strains.
The definition of CA-MRSAhas not been standardized.
No single definition would likely suffice for all purposes.
Attempts to define CA-MRSAhave focused upon a variety
of criteria: temporal (i.e., the MRSA isolate from a speci-
men is submitted <72 hours after hospital admission),
host-risk-factor profile (i.e., the patient with the MRSA
isolate lacked certain exposure parameters relevant to
healthcare facilities, variously defined), antimicrobial drug
susceptibility of the MRSA isolates (e.g., susceptibility to
clindamycin), and certain molecular aspects of the isolates
(e.g., SCCmec type or pulsed-field gel electrophoresis
type). Which definition is most important in the choice of
empiric antimicrobial drug treatment is not clear.
However, a clinician confronted with a putative S. aureus
infection needs guidance.
The epidemiology of the emerging CA-MRSA strains,
including their origins, reservoirs, modes of dissemination,
and effective approaches to their control, is not complete-
ly understood. We previously noted that CA-MRSA iso-
lates often lacked resistance to multiple non–β-lactam
antimicrobial drugs when compared with HA-MRSA
strains (5,6). This phenomenon has been documented in
adults (4,7) and children (8–10). More recently, we anec-
dotally observed that children had MRSA infections
caused by strains susceptible to non–β-lactam antimicro-
bial drugs more often than adults. Few data exist that com-
pare antimicrobial drug resistance profiles of adult and
pediatric MRSAinfection isolates stratified by site of onset
(hospital vs. community). Accordingly, using the temporal
definition of CA-MRSA, we examined the hypothesis that
these 2 groups may be infected by MRSA strains with dif-
ferent rates of resistance to non–β-lactam antimicrobial
drugs when the isolates had onset in the community.
Therefore, we compared several criteria for the temporal
definition of CA-MRSA to assess the impact of changing
these criteria on our findings. This article summarizes our
study.
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The University of Chicago Hospitals (UCH) is a terti-
ary-care medical center on the south side of Chicago with
577 inpatient beds and 29,500 annual admissions. It
includes an outpatient care facility with 379,000 annual
visits. UCH serves an inner city population and draws ter-
tiary referrals from the surrounding region. 
The UCH Clinical Microbiology Laboratories prospec-
tively identified all MRSAisolates collected at the medical
center from November 7, 2003, to November 7, 2004,
from inpatients and outpatients. S. aureus isolates were
identified by gram stain, growth on BBL mannitol salt fer-
mentation agar (Beckton, Dickinson and Company,
Sparks, MD, USA), positive catalase test results, and a
positive Staphaurex Plus test (Remel Europe Ltd.,
Dartford, UK) result.
The Clinical Microbiology Laboratories determined the
susceptibility profile of each isolate by using the Vitek 2
system (bioMérieux Vitek, Inc., Durham, NC, USA) for
methicillin, erythromycin, clindamycin, ciprofloxacin,
rifampin, gentamicin, tetracycline, and vancomycin. From
November 7, 2003, to July 2004, any isolate with an MIC
of vancomycin >2 µg/mL reported by the Vitek system
was retested for vancomycin susceptibility by the Etest
Strip (AB Biodisk, Solna, Sweden). After July 2004, the
Etest was performed for these isolates only if growth
occurred on a vancomycin agar screen plate. For isolates
that tested resistant to erythromycin but susceptible to clin-
damycin, a D-test to detect inducible resistance to clin-
damycin was performed, as was a Kirby-Bauer
disk-diffusion test for susceptibility to trimethoprim-sul-
famethoxazole (TMP-SMX), both according to Clinical
and Laboratory Standards Institute (CLSI) guidelines (35).
For each MRSAspecimen, patient information was col-
lected from the laboratory information system and the
electronic medical record, including the date of specimen
procurement, age and sex of the patient, location of speci-
men procurement (inpatient, outpatient, emergency depart-
ment), and antimicrobial drug susceptibility profile. For
inpatient isolates, the number of days from admission to
culture procurement was determined by subtracting the
admission date from the procurement date.
We defined CA-MRSA to include all isolates cultured
from outpatients and isolates from hospitalized patients
obtained within 72 hours of admission. We also examined
the impact of changing the 72-hour criterion in the defini-
tion to 24 and 48 hours. With each change in definition, the
effect on the percentage of MRSAinfections considered to
be community associated was assessed.
The bacteriologic and patient information was com-
piled in an electronic database designed for the study by
using Access software (Microsoft, Redmond, WA, USA).
Only the first isolate from each patient collected during the
surveillance was included in the database. The study was
approved by the institutional review board of the
Biological Sciences Division of the University of Chicago.
Data were analyzed with Stata, version 8.0 (Stata Corp,
College Station, TX, USA). Comparisons between groups
were performed by the χ2 test or the Fisher exact test. All
hypotheses were 2-tailed and were considered significant
if p<0.05.
Results
The UCH Clinical Microbiology Laboratories identi-
fied 1,149 MRSA-positive cultures from 578 patients. Of
these, 201 (34.7%) were from children <18 years of age
and 377 (65.3%) were from adults >19 years of age. Of the
adult MRSA isolates, 27.9% were cultured from outpa-
tients; of the pediatric MRSA isolates, 57.2% were cul-
tured from outpatients. The median age of pediatric
patients was 3 years (16 days to 18 years), with a median
of 6 years among outpatients and 2 years among inpatients.
For adults, the median age was 56 years (range 19–100),
with a median of 51 years among outpatients and 60 years
among inpatients.
Using the 72-hour definition, 64.3% of adult and 72.1%
of pediatric inpatient isolates were CA-MRSA (p = 0.2)
(Table 1). Restricting the definition of CA-MRSAto the 48-
hour definition, 58.5% of adult and 69.8% of pediatric inpa-
tient isolates were CA-MRSA(p = 0.06). Fifty-four percent
and 65.1%, respectively, of adult and pediatric inpatient iso-
lates met the criteria for the 24-hour definition of CA-
MRSA (p = 0.07). Thus, by using the 24-, 48-, or 72-hour
criteria for CA-MRSA, most of the pediatric and adult inpa-
tient isolates would be considered community-associated.
Combining the isolates cultured in the emergency
department with those cultured in clinics, 105 outpatient
isolates were obtained from adults and 115 from children.
Adult isolates were substantially more likely than pediatric
isolates to be resistant to ciprofloxacin, clindamycin, gen-
tamicin, and tetracycline. No difference was seen in resist-
ance rates for erythromycin or rifampin (Table 2).
A small percentage of the temporally defined CA-
MRSA isolates (i.e., those either from outpatients or cul-
tured <72 hours after admission from inpatients) was
resistant only to β-lactam antimicrobial drugs; this resist-
ance pattern was more common among pediatric (9.6%)
than adult (3.6%) isolates (p = 0.001) (Table 3). Among the
temporally defined CA-MRSA isolates, those from adults
were more likely than those from children to be resistant to
most of the non–β-lactam antimicrobial drugs. The rate of
resistance to erythromycin was high among both the pedi-
atric and adult isolates, although significantly higher
among the adult isolates. The rate of resistance to clin-
damycin, ciprofloxacin, gentamicin, and tetracycline was
much higher for adult than for pediatric CA-MRSA
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rifampin, TMP-SMX, or vancomycin.
The D-test for inducible clindamycin resistance was
performed on 97% (112/116) of adult and 89% (125/142)
of pediatric CA-MRSA isolates that were resistant to
erythromycin and susceptible to clindamycin. Among
those tested, adult (20.5%, 23/112) isolates were more
likely than pediatric (15.2%, 19/125) isolates to have a
positive D-test result (Table 3).
In contrast to the differences we found among CA-
MRSAisolates from adults and children, however, the hos-
pital-associated MRSA isolates (>72 hours after
admission) had similar rates of antimicrobial drug resist-
ance (Table 3). For example, clindamycin resistance
occurred in 74.2% of adult and 75.0% of pediatric HA-
MRSAisolates (p = 0.9). Only the rates of ciprofloxacin (p
= 0.004) and gentamicin (p = 0.01) resistance were sub-
stantially different when the HA-MRSA isolates were
compared (Table 3).
We defined a multidrug-resistant (MDR) MRSAisolate
as being resistant to >3 of the non–β-lactam antimicrobial
drugs tested. When the temporal definition (<72 hours
after admission) was used, adult CA-MRSA isolates were
more likely than pediatric CA-MRSA isolates (52.3% vs.
6.4%, p<0.0001) to be MDR (Table 3). HA-MRSAisolates
from both children and adults were more often MDR, but
the rates did not differ substantially (76% vs. 66.7%, p =
0.4) (Table 3).
Discussion
When community association or onset was defined by
using the temporal criterion of procuring isolates <72
hours after admission, most adult and most pediatric
MRSAisolates in our study would be considered to have a
community origin. A narrower procurement definition,
e.g., <24 hours or <48 hours, would have led to the same
conclusion.
MRSA isolates from children’s specimens compared
with isolates from adults’ specimens obtained <72 hours
after admission were more likely to be resistant to only β-
lactams and more likely to be susceptible to clindamycin,
ciprofloxacin, and gentamicin. These differences suggest
that there may be distinct CA-MRSA isolates colonizing
and infecting children and adults in the population served
by our medical center or, less likely, that there may be a
reservoir of CA-MRSAthat affects children and adults dif-
ferently.
Children may have unique risk factors for MRSA colo-
nization in the community related to their environment,
such as daycare centers (11,12), schools (13), or recre-
ational facilities, and may have different behavioral habits
than most adults. Alternatively, children may be different
from adults as hosts, and they may encounter novel MRSA
strains either by different colonization of the skin or by
some undefined difference in host defense. Antimicrobial
drugs used to treat infections among children may differ
from those used among adults; perhaps distinct MRSA
strains colonizing children result from differential antimi-
crobial drug selection pressures in the community.
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therapy of CA-MRSAinfections and MRSAcontrol meas-
ures. In the population served by UCH, for children with
suspected community-onset MRSA infections, clin-
damycin is an appropriate first-line empiric antimicrobial
drug, at least for those who are not critically ill (8,10). In
adults, by contrast, clindamycin would be much less suit-
able in this role, as most temporally defined CA-MRSA
isolates are clindamycin-resistant. Therefore, among
adults at our institution, clindamycin can be considered
only after susceptibility testing results have been obtained
from a culture specimen. 
CA-MRSA isolates from children have a low rate of
clindamycin resistance. Studies of children with CA-
MRSAinfections or colonization in many cities, including
Houston, Corpus Christi, Memphis, Nashville, Louisville,
Providence, and Chicago, have demonstrated high rates of
clindamycin susceptibility among these isolates, ranging
from 67%–100% (1,8,10,14–16). The 2 studies with the
lowest susceptibility rates were conducted in Providence
from 1997 to 2001 with a 74% rate (8),and Louisville from
1999 to 2001 with a 67% rate (16). These lower rates may
have been due to geographic variation or were a window
on an earlier phase in the CA-MRSA epidemic.
A possible confounder in calculating clindamycin
resistance rates is the 2004 CLSI guideline stating that
each isolate that initially tests susceptible to clindamycin
and resistant to erythromycin should be tested for
inducible clindamycin resistance by the D-test; if the test
result is positive, that isolate should be considered resist-
ant (35). Published data from before 2004 may not have
included D-test results in reporting clindamycin resistance
rates among MRSA isolates. However, the impact of the
new CLSI guideline does not change the conclusions
derived from our data, although the rate of clindamycin
resistance among all pediatric MRSA isolates in our sam-
ple would increase from 15.4% to 24.9% when the new
guideline was considered.
We have continued to use clindamycin for initial empir-
ic therapy of mild or moderately ill pediatric patients like-
ly to have a CA-MRSA infection. We take this approach
because better alternative therapy is not available. The
results of TMP-SMX therapy for CA-MRSA have been
reported for relatively few patients (36); therapy was fre-
quently unsuccessful despite in vitro susceptibility of the
infecting MRSA strains. Tetracyclines are not suitable for
young children, and linezolid is prohibitively expensive.
Our policy is to abandon clindamycin when susceptibility
testing or D-test results suggest the possibility of treatment
failure, usually 2–4 days into the treatment course or, as
mentioned, for severe illness when CA-MRSA is suspect-
ed. To date, this approach has been suitable.
The pattern of clindamycin resistance among adult CA-
MRSA isolates has been more complex. At UCH, more
than half of the CA-MRSA isolates from adults were
resistant to clindamycin. Similarly, at Northwestern
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few MRSA isolates were clindamycin susceptible among
those that were collected <72 hours after admission from
adults with no known hospitalizations in the previous 2
years (37).
In contrast, more recent studies of CA-MRSA infec-
tions and MRSA colonization isolates have demonstrated
low rates of clindamycin and other non–β-lactam resist-
ance among MRSA isolates from young and urban poor
adults. For example, 9 of 67 patients with MRSA infec-
tions in a military-beneficiary population in Texas from
1999 to 2001 had no risk factors for HA-MRSA. These
patients all had onset of infection in the community and
had an isolate that was susceptible to clindamycin.
Moreover, they were younger than the patients reported to
have HA-MRSA infections (4). In San Francisco in
1999–2000, among asymptomatic, homeless and margin-
ally housed adults in the community, 23 MRSA isolates
were identified from nasal swabs of which only 2 (8.7%)
were resistant to clindamycin (17). In a sample of 45 colo-
nizing and infecting MRSAisolates collected from healthy
young adults (18–44 years of age) training at a military
facility in Texas, 22% were resistant to clindamycin (7).
Why these disparities exist in the rates of clindamycin
susceptibility among CA-MRSA isolates obtained from
adults is unclear. Possible explanations include regional
variation or characteristics of the patient populations sam-
pled. The 2 studies with high clindamycin resistance rates
were both conducted in Chicago at tertiary medical cen-
ters.  Community-based surveys among adults, in contrast,
have demonstrated a high rate of clindamycin susceptibil-
ity, perhaps reflecting an exposure to a community MRSA
isolate pool similar to the pool affecting pediatric popula-
tions in many urban centers.
Unlike clindamycin, erythromycin resistance has been
common among both pediatric and adult CA-MRSA iso-
lates. In hospitalized children with MRSA infections at
UCH during 1988–1990 and 1993–1995, 74.3% carried
isolates resistant to erythromycin (5). Our current rate,
88.1% in pediatric isolates, is slightly higher.
Erythromycin resistance has also been common among
CA-MRSA isolates colonizing and infecting children at
many urban centers from 1990 to 2002, with rates from
52% to 100% (8,10,14,16). In adults, recent studies have
shown similarly high rates of erythromycin resistance,
60.9%–80%, among CA-MRSAstrains in selected popula-
tions, including soldiers (7), inmates in jail (38), and
homeless and impoverished urban adults (17).
Analysis of antimicrobial resistance patterns among
MRSA isolates obtained >72 hours after admission pro-
duced a sharp contrast with the CA isolates. Children and
adults in this HA group were infected by MRSA strains
with similar rates of resistance to non–β-lactam antimicro-
bial drugs. This finding suggests that adults and children
face a common source of antimicrobial drug selection
pressure and a common reservoir of MRSA isolates in our
hospital, but not in the community.
Before this study, few data have been available to com-
pare the resistance patterns of MRSA isolates collected in
1 medical center or region stratified by both age group
(children vs. adults) and venue of onset (community vs.
hospital). One previous analysis conducted from 1988 to
1997 at another medical center in Chicago compared adult
and pediatric MRSA isolates and also found that MRSA
strains susceptible to clindamycin were more common
among pediatric than adult isolates; the isolates were not
stratified by hospital or community origin (18). In contrast,
among CA-MRSA isolates collected during 2000 from 12
Minnesota clinical microbiology laboratories serving both
inpatients and outpatients, no differences in the rate of
clindamycin susceptibility were found in isolates from
children and adults (19). These investigators used a
risk–factor-based definition for CA-MRSA, while we used
a temporal definition. Other possible explanations for the
discrepancy include a secular change in the 4 years sepa-
rating the studies or demographic differences in the study
populations.
Our study has certain limitations. It was conducted in 1
center and in 1 city, and it is unknown whether our data are
representative of the CA-MRSA epidemic in other areas.
Our study also assumes that adults and children seeking
care in all areas of our medical center had an approximate-
ly equal chance of having a culture performed. We did not
evaluate whether an assessment of risk factors for HA-
MRSAwould have determined the likelihood of resistance
to non–β-lactam antimicrobial drugs.
With the recognition of CA-MRSA as a distinct epi-
demiologic phenomenon and the accompanying upsurge in
both the S. aureus disease burden and methicillin resist-
ance rates at many centers, considerable controversy has
surrounded the definition most appropriate for CA-MRSA.
Whether the best definition should be based on temporal,
molecular, antimicrobial drug susceptibility, or host risk-
factor criteria will not be resolved by this study and will
continue to vary according to the issue being addressed.
Despite these uncertainties, our data, using the temporal
definition, have practical value in the initial antimicrobial
drug management of patients with suspected CA-MRSA
infections. 
Understanding the complex epidemiology of CA-
MRSA infection is critical to the development of control
policies and treatment guidelines in areas with a high col-
onization and disease prevalence. Our data demonstrate
the complexity of the contrasting definitions of CA-
MRSA. While neither a time criterion alone nor a time
criterion in addition to an antimicrobial drug susceptibility
Contrasting Pediatric and Adult MRSA Isolates
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valuable guidance for clinical practice.
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